Objective: To investigate the influence of metabolic syndrome (MS) on risk stratification and ulterior classification in hypertensive patients at entry into a hypertension unit by comparing the criteria of ESH-ESC 2003 and 2007 guidelines. Methods: 720 consecutive patients attending a hospital-located hypertension unit were included in the study. They were classified with or without MS according to the ATP-III 2005 report. Patients underwent repeated office BP measurements and routine blood/urine examinations. In addition ultrasensitive CRP (uCRP), echocardiogram, fasting insulin, urinary albumin excretion were determined and HOMA index was calculated. Results: The prevalence of MS was 58.8 %. Abdominal obesity and fasting glucose were the most prevalent components of MS, and HDL-cholesterol the least prevalent. MS group had higher levels of LDL-cholesterol and higher prevalence of left ventricular hypertrophy and microalbuminuria. Patients with MS also presented a significant elevation in uCRP, fasting insulin and HOMA. BP was controlled in 55.6%. When we applied the 2003 guideline, 48.9% patients showed a high or very high added cardiovascular risk. With the applications of the 2007 guide the prevalence of this two categories reach 73.9%. Conclusions: A significant difference in the risk pattern distribution is found when MS is considered in risk stratification in our hypertensive population. The accompanying increase in the levels of other cardiovascular risk factors and in the prevalence of target organ damage justifies the global intervention on cardiovascular risk recommended by 2007 ESH-ESC guidelines.
Introduction
For a long time hypertension guidelines focused on blood pressure values as the only or main variables determining the need and the type of treatment. The 2003 ESH-ESC Guidelines [Guidelines Committee, 2003 ] emphasized that diagnosis and management of hypertension should be related to quantification of total cardiovascular risk. Furthermore, when concomitantly present, blood pressure and metabolic risk factors potentiate each other, leading to a total cardiovascular risk that is greater than the sum of its individual components [Kannel, 2000] . Finally, evidence is available that in high-risk individuals, thresholds and goals for antihypertensive treatment, as well as other treatment strategies, should be different from those implemented in lower risk individuals [Guidelines Committee, 2003] . In order to maximize cost-efficacy of the management of hypertension the intensity of the therapeutic approach should be graded as a function of total cardiovascular risk.
Estimation of total cardiovascular risk is simple in particular subgroups of patients such as those with a previous diagnosis of cardiovascular disease, type 1 and type 2 diabetes, and individuals with severely elevated single risk factors. In all these conditions the total cardiovascular risk is high. However, a large number of hypertensive patients do not belong to one of the above categories and identification of those at high risk requires the use of models to estimate total cardiovascular risk so as to be able to adjust the intensity of the therapeutic approach accordingly. The relative value of the different definitions of the metabolic syndrome (MS) in terms of clinical management and prognosis has not been clearly determined. For this reason, prevalence of this syndrome is not uniform in the studies analyzed around the world, since they differ based on age, presence of obesity and diabetes circumstances which increase its prevalence [Ford et al. 2002] and also on the different ethnic groups studied [Tan, 2004] . Prevalence has further increased in the last decade in close relationship with the increased level of obesity of the Western population [Lorenzo et al. 2006 ] and also with the application of the ATP III-2005 criteria [Grundy et al. 2005] or IDF [Ford, 2005] . An increase in MS prevalence in comparison with that of normotensive subjects has also been observed in the hypertensive population [Rantala et al. 1999 ].
On the other hand, the presence of metabolic syndrome is associated with a greater risk of developing type II diabetes (DM) [Mancia et al. 2007a; Lorenzo et al. 2003 ] and a significant increase of ischemic heart disease [Nigam et al. 2006 ] cerebrovascular disease [Kurl et al. 2006 ] and heart failure [Ingelsson et al. 2006 ]. In many studies, both in Europe and in the United States, the increase in global cardiovascular morbidity mortality is two-fold [Dekker et al. 2005 ]. Furthermore, cardiovascular risk has doubled in a follow-up over 10 years in hypertensive people with metabolic syndrome [Schillaci et al. 2004 ]. The mechanisms underlying MS are not well known. However, it is believed that insulin resistance may be a common factor to many of the patients who suffer MS and also the hypertensive subjects [Burattini et al. 2006; Ferranini, 2006 ]. The ESH-ESC 2007 [Mancia et al. 2007b guidelines included the metabolic syndrome because it represents a cluster of risk factors often associated with high blood pressure which markedly increases cardiovascular risk.
The primary objective of this study was to establish the distribution of cardiovascular risk in a hypertensive patient population seen in a hospital-located hypertension unit in Spain using in a comparison between the criteria of ESH-ESC 2003 Guidelines [Guidelines Committee, 2003 and those published in the 2007 ESH-ESC Guidelines. To this end we studied the prevalence of the metabolic syndrome, using NCEP (ATP-III) criteria. The objective also includes a description of the global cardiovascular risk of these subjects and the differences in risk factors and in target organ lesion between the subpopulations of subjects with and without metabolic syndrome. Finally, it aims to study the possible differences in the degree of insulin resistance and inflammatory patterns in both groups.
Material and methods
A descriptive and cross-sectional study was performed in all hypertensive patients attending in the HBP Unit of the San Carlos Clinic Hospital, Madrid, Spain, during October, November and December 2007. Based on the mean number of patients seen in the unit during a 12-week period it was initially estimated that at least 600 patients would be included in the study with a prevalence of metabolic syndrome of around 3040%. The study was approved by the ethics committee of the hospital and a written informed consent was obtained from every patient. The final sample included was 720 Caucasian patients.
The following clinical and laboratory parameters were collected: age, gender, weight, height, body mass index, abdominal diameter, blood pressured collected according to ESC-ESH 2007 criteria; associated cardiovascular risk factors and associated clinical conditions, such as angina and myocardial infarction, heart failure, cerebrovascular disease or kidney failure. We searched for subclinical organ damage. Left ventricular hypertrophy (LVH) was measured by echocardiogram according to Devereaux criteria [Devereaux and Reichek, 1997] . LVH was defined as a LV mass index !125 g/m 2 for men and !110 g/m 2 for women. We screened for microalbuminuria, collecting three spot urines on three different days. We expressed the results as an average of the three and related them to urinary creatinine excretion. Of the patients entering the study, 92.2% were on treatment, 17.8% on monotherapy, 25.6% on double therapy and 56.6% on three or more antihypertensive drugs. The following data were collected from the laboratory analysis performed after an overnight period of fasting in the current visit: serum glycemia, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, uric acid, and creatinine. Creatinine clearance was calculated according to the Cockroft-Gault equation [Cockroft and Gault, 1976] . Data on insulin resistance measured as insulinemia, HOMA index [Matthews et al. 1985] triglyceride/HDL ratio, and ultrasensitive C-reactive protein (uCRP) were also collected. The HOMA index was not estimated in patients receiving insulin therapy.
The presence of metabolic syndrome was diagnosed following criteria of the ATP III 2005 [Grundy et al. 2005] . A digital validated sphygmomanometer (OMRON) was used to record blood pressure with the patient in the sitting position, performing two consecutive measurements separated by a two-minute interval. To calculate cardiovascular risk, the 2003 and 2007 ESH-ESC guidelines were used. Blood pressure levels, renal and cardiac lesions were considered according to the criteria also established by these guidelines.
Statistical analysis
A descriptive analysis of the study data has been made by elaborating frequency tables for nominal-type variables. Regarding the latter ones, 95% confidence intervals (95% CI) have been estimated. To analyze the possible association between MS with certain clinical and biochemical variables, these variables were compared between subjects who fulfilled or did not fulfil the criteria of one disease or another with the Chi-squared test or the exact Fisher's test for qualitative variables and the Student's t-test for independent data or the Mann-Whitney U-test, or ANOVA for quantitative variables. In every case, the confidence level was established at 95%. All the calculations were made with the SAS statistical program.
Results
The clinical-laboratory analysis characteristics of the patients are detailed in Table 1 . Positive family history of early cardiovascular disease was found in 2.2% of the patients. A total of 6.9% were smokers (74% men and 26% women). Control rate of BP (<140/90 mmHg, <130/80 mmHg in diabetic patients) was 55.56%. Left ventricular hypertrophy was detected in 185 patients (25.7%). Of these, 116 (62.5%) were men and 69 (37.3%) were women. Prevalence rate of LVH was 31.2% in men and 19.8% in women.
Ninety percent of the patients had fasting glycemia values equal to or greater than 100 mg/dl or followed treatment for their diabetes. A total of 88.7% had abdominal obesity, 44.2% had elevated triglyceride values and/or received specific treatment for this and only 20.5% of the patients with MS had low HDL values. MS prevalence in the unit was 58.82%. When we applied the IDF-2005 criteria to this same population, MS prevalence reached 69.8%.
Significant differences were found between the groups with and without metabolic syndrome in the following variables: age, weight, BMI, abdominal circumference, SBP and laboratory analysis values: LDL cholesterol, HDL cholesterol, triglycerides, uric acid and albumin excretion (Table 2) . Differences were found for cardiac damage with a prevalence of LVH diagnosed by echocardiogram significantly greater in the subgroup with metabolic syndrome (32.41% versus 22.06%; p < 0.0001).
Differences in insulin resistance pattern are shown in Table 3 . Baseline insulinemia, HOMA indexes and triglyceride/HDL ratio were significantly greater in the hypertensive group with metabolic syndrome. A positive statistically significant trend between the number of MS components and the HOMA index value was detected (Table 4) . Similarity, the grade of inflammation, measured by the assessment of ultrasensitive CRP, is significantly greater in the MS hypertensive group (Table 2) . Therapeutic Advances in Cardiovascular Disease 4 (2)
Discussion
The prevalence of metabolic syndrome detected in our hypertension unit is 58.8% when we apply the 2005 NCEP-ATP III criteria. Although somewhat less, this comes close to that described in a recent MS prevalence study in hypertensive subjects (62.9%) conducted in the USA with the same criteria [Ford, 2005] . Cordero et al. [2006] observed a 30% prevalence in Spanish male hypertensive subjects of working age. In a reference hypertension unit, Cuspidi et al. [2004] found a 30.2% prevalence of MS in untreated essential grade I and II hypertensive subjects and Mulè et al. [2005] also described a 37% prevalence in hypertensive subjects without treatment or after 2 weeks of washout. In the present study, all our population presented with hypertension (55.6% controlled), and the next most prevalent individual component was elevated fasting plasma glucose level (90.8%). The third was abdominal obesity (87.8%), the last two factors being in concordance with the type of population studied in our unit that is older (mean age: 60 years) and obese (mean BMI: 29.9 kg/m 2 ). In the San Antonio study it has been demonstrated the MS prevalence also increases as the degree of obesity increases [Lorenzo, 2006] . In the present study the lipid disorders of MS were less prevalent, the prevalence of decreased levels of HDL cholesterol being especially low. This only occurred in 20.5% of the hypertensive subjects with MS contrary to that found by Cuspidi et al. [2004] , who found that low concentrations of HDL were the most frequent component. We consider that the mean HDL cholesterol in the total sample is high (56.9 mg/dl). That has been demonstrated as characteristic of the Spanish population, even in childhood [Gó mez-Gerique et al. 1999] .
In this study, the degree of BP control was 55.6% superior to that obtained in other works conducted in specialized units of HBP in Spain [Banegas et al. 2004] . An increase in albumin urinary excretion and in uric acid serum levels has also been found, confirming the results obtained by other groups [Mulè et al. 2005; Cuspidi et al. 2004 ]. However, we have not found any differences in serum creatinine or creatinine clearance values.
In these hypertensive subjects, insulin resistance increases when more components of those defining the syndrome are grouped together. The causeeffect relationship between insulin resistance and hypertension or even if both situations are derived from an underlying process, have been discussed in depth. It has been demonstrated in epidemiological studies with normotensive subjects that altered sensitivity to insulin predicts the increase in blood pressure [Ä rnlöv et al. 2005 ] and that prehypertension is associated with an increase in insulin resistance markers [Cordero et al. 2006 ]. The data of the present study tend to support the importance of insulin resistance in the metabolic syndrome and the relationship between it and the number of components of the syndrome. This suggests a relevant role in its pathophysiology.
There is a proinflammatory state in MS confirmed in the present study by ultrasensitive CRP that is higher in MS hypertensive patients. Increase in inflammatory markers (CRP) in MS indicates subclinical atherosclerosis and has been associated with the presence of obesity, insulin resistance and altered leptin levels, constituting the underlying cardiovascular disease process [Schindler et al. 2006 ].
In patients with MS, additional administration of antihypertensive, lipid lowering drugs or aspirin is required. However, some hypertensive patients with MS glycemic and lipids levels do not reach levels of drug intervention. In these groups of patients, the cardiovascular risk is high and it would appear advisable to pursue a rigorous blood pressure control. At present, no unifying pathogenenic mechanism is identified that could explain the MS and hence there is no unique treatment. Considering MS both as a proinflammatory and insulin resistance state and taking into account the high cardiovascular risk of these patients we could consider that the treatment must include statin, aspirin or instead any other drug with effects on PPAR-receptor, or drugs that act through a unique mechanism to exert their effects on cardiometabolic risk independent of weight loss alone. Modulating the activity of the endocannabinoid system holds promise as an approach to treating obesity, dyslipidaemia and atherogenesis which are associated with MS [Pi-Sunyer et al. 2006 ]. Unfortunately these drugs are not available today.
Our results clearly indicate that applying risk assessment according to recent guidelines is associated with a significant increase in the number of hypertensive patients at high risk of cardiovascular disease. These results support the hypothesis that the identification of high-risk hypertensive patients could have a great economic impact on healthcare plans that should be take into account in the effective prevention of a further deterioration of arterial ageing.
